Plunkett Research Online: Genmab A/S

GENMAB A/S (GMAB:NAS) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab’s proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the stan.....



Genmab A/S
Ticker: GMAB
Exchange: NAS
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 45 70202728
Fax: 45 70202729
Address: Kalvebod Brygge 43
Copenhagen V, 1560 Denmark

Map
Types Of Business
Industry Ranks

Industry NAICS code:

Pharmaceuticals
Contacts Description
Jan van de Winkel CEO/Co-Founder/President
Anthony Pagano CFO/Executive VP
See More

Auditor: PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab
Legal Advisor:
$USD, In whole numbers,
except marked * or %
2020 2019 2018 2017 2016 2015
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and Affiliates Top Salaries
Name Title Salary (DKK) Bonus (DKK)
Other Thoughts Corporate Culture

Apparent Female Officers or Directors: